Literature DB >> 22372591

Effects of oestrogen and testosterone therapy on serum metabolites in postmenopausal women.

Hong Zang1, Thomas Moritz, Gunnar Norstedt, Angelica L Hirschberg, Petra Tollet-Egnell.   

Abstract

OBJECTIVES: Metabolite profiles of body fluids or tissue extracts can be regarded as important indicators of physiological or pathological states. Whether hormone-specific alterations of the serum metabolome can be identified using this technique has not been tested yet. The aim of this study was to investigate metabolic responses during hormone therapy in postmenopausal women by a nontargeted metabolomics approach.
METHODS: Sixty naturally postmenopausal women were randomly assigned to treatment with testosterone undecanoate 40 mg every second day; estradiol valerate 2 mg daily; or the combination of both. Serum metabolites were determined by gas chromatography-mass spectrometry (GC-MS) before and after 3 months of treatment. Metabolites affected by the treatment were identified and correlated with changes in insulin sensitivity and lipid profiles.
RESULTS: Treatment-dependent and hormone-specific effects on serum metabolites were observed, ranging between 69% reduction and 184% increase, but the metabolites that best explained the differences could not be structurally identified. Effects on annotated metabolites were less associated with clinical parameters as compared to established serum markers for adverse lipid and carbohydrate metabolism, such as cholesterol and triglycerides. However, cystine, lysine and tyrosine were shown to change in correlation with insulin sensitivity and high-density lipoprotein cholesterol levels in response to testosterone, indicating that those responses were somehow related to each other.
CONCLUSIONS: Oestrogen- and androgen-specific alterations in the serum metabolome could be identified using GC-MS, reflecting hormone-specific effects on whole body metabolism. New knowledge regarding steroid-mediated metabolic responses within different tissues might be obtained using a similar approach on tissue extracts.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372591     DOI: 10.1111/j.1365-2265.2012.04374.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Serum metabolomic profiles associated with postmenopausal hormone use.

Authors:  Victoria L Stevens; Ying Wang; Brian D Carter; Mia M Gaudet; Susan M Gapstur
Journal:  Metabolomics       Date:  2018-07-06       Impact factor: 4.290

2.  Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women.

Authors:  Gordon I Smith; Dominic N Reeds; Adewole L Okunade; Bruce W Patterson; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2014-04-02       Impact factor: 5.958

3.  12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study.

Authors:  Matthias K Auer; Alexander Cecil; Yasmin Roepke; Charlotte Bultynck; Charlotte Pas; Johannes Fuss; Cornelia Prehn; Rui Wang-Sattler; Jerzy Adamski; Günter K Stalla; Guy T'Sjoen
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

4.  The Metabolomic Rationale for Treating Perimenopausal Syndrome as Kidney Deficiency.

Authors:  Xueqin Chen; Caiming Wu; Wen'na Liang; Jianying Shen; Zewei Zhuo; Liu Hu; Luwei Ruan; Pengheng Zhang; Leqin Xu; Chengfu Li; Shengyuan Lin; Junjie Lan; Haixia Ren; Hongwei Yao; Tongjin Zhao; Bizhen Gao; Tianwei Lin; Huiying Huang; Candong Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-09       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.